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INCREASING ASPIRIN ADHERENCE IN PREGNANT WOMEN AT RISK FOR 
PREECLAMPSIA 
SAMANTHA OLSZEWSKI 
ABSTRACT 
Hypertensive disease in pregnancy, including preeclampsia, is the leading cause of 
perinatal morbidity and mortality in the United States. Preeclampsia, characterized by 
new onset hypertension and proteinuria, can cause seizures, cerebral hemorrhage, 
pulmonary edema, placental abruption, premature birth, and death. The only definitive 
treatment for preeclampsia is delivery of the fetus. However, studies have shown that 
daily low dose aspirin (LDA) can reduce the risk of preeclampsia without increasing 
negative outcomes, such as bleeding. Despite this evidence, LDA has yet to be 
implemented routinely in prenatal care in the United States.  
The aim of this study is to improve LDA implementation by increasing adherence 
to the medication once it is prescribed by the provider. While some studies have shown 
that providing patient education or increasing family support increases medication 
adherence, very few studies have assessed medication adherence in a pregnant 
population. Even fewer studies have assessed adherence to LDA to prevent preeclampsia. 
We are proposing a quality improvement project within the OBGYN clinic at Boston 
Medical Center to assess the barriers to medication adherence, to identify effective 
patient-directed implementation strategies to increase adherence, and to reach an 
adherence rate of 90% in twelve months. Identifying and implementing effective 
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strategies to increase medication adherence to LDA has the potential to reduce the rate of 
preeclampsia and the associated negative perinatal outcomes. 
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INTRODUCTION 
Background 
Hypertensive disease in pregnancy is responsible for more than 33% of maternal 
morbidity and 12% of maternal deaths1. Preeclampsia is one of the most common types 
of hypertensive disease, associated with 3.8% of pregnancies in the United States in 
20102. Risk factors of preeclampsia include a personal or family history of preeclampsia, 
multiple gestation, diabetes mellitus, hypertension, African American race, and low 
socioeconomic status2. Complications of preeclampsia for the infant include preterm 
birth, intrauterine growth restriction, and rarely, still birth3. Maternal complications of 
preeclampsia include seizures, pulmonary edema, end organ damage, and rarely, death3. 
Recent research has shown that low dose aspirin (81 mg) can significantly reduce the risk 
of preeclampsia and preterm birth2,4. Preterm birth is the leading cause of infant 
morbidity and mortality in the United States and is associated with billions of dollars of 
healthcare spending annually5. Therefore, it is imperative that patients at risk for 
preeclampsia be treated prophylactically with LDA daily to prevent negative maternal 
and fetal outcomes.   
 
Statement of the Problem 
Despite the evidence that LDA can reduce the incidence preeclampsia, many women who 
meet criteria for LDA do not take it. Increasing the implementation of LDA into routine 
prenatal care can be studied with implementation science. The goal of implementation 
science is to ensure that evidence-based findings are carried out into clinical practice. 
  2 
Several tools have been created to guide the implementation process (Appendix); 
however, as a relatively new field of study, objective data is both limited and equivocal 
on which interventions are the most efficacious for various clinical situations. For 
example, a meta-analysis performed by Grimshaw et al found that the most effective 
implementation strategies, non-specific to medication adherence, include reminders and 
educational outreach, while the least effective strategies include passive dissemination of 
materials (i.e. mailing guidelines to healthcare professionals)6. Grimshaw et al found no 
significant difference in provider behavior or patient outcome if a single intervention or 
multifaceted interventions were used6. Yet, another meta-analysis found that multiple 
implementation strategies were more likely to increase implementation and improve 
outcomes rather than a single approach7. Finally, it is also thought to be important to first 
identify specific barriers to implementation, or determinants of practice, in order to 
choose an intervention that best addresses those barriers and produces the most change. 
Currently, there are no reliable data which objectively pair implementation strategies to 
determinants of practive8.  
As a result, there is limited data on objective, universal strategies to increase 
medication adherence. While there are studies assessing barriers and facilitators to 
medication adherence in a pregnant population, there is limited data on effective 
interventions for improving adherence. Even less is known about effective interventions 
to increase adherence with daily LDA for pregnant women at risk for preeclampsia.   
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Hypothesis 
Implementing patient-directed intervention strategies will increase adherence to LDA in 
pregnant women at risk for preeclampsia. 
  
Objectives and specific aims 
A quality improvement project will be performed in order to increase adherence rates of 
LDA in pregnant women at risk for preeclampsia at BMC. The stakeholders that will be 
addressed in this study are the patients.  A barrier analysis will be performed and 
interventional strategies will be chosen based on those results. Several plan-do-study-act 
(PDSA) cycles will be performed in order to determine the most effective interventions. 
The following are the specific aims of the study: 
•   To identify barriers to medication adherence in patients prescribed LDA for 
preeclampsia prophylaxis 
•   To determine which interventions are most effective in increasing LDA adherence 
rates 
•   To increase adherence to LDA in at risk pregnant women within BMC system to 
90% in 12 months  
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REVIEW OF THE LITERATURE 
Overview 
Hypertensive disease in pregnancy  
  
Hypertensive disease in pregnancy is one of the most common causes of maternal and 
perinatal morbidity and mortality and includes: 1) preeclampsia and eclampsia 2) 
gestational hypertension 3) chronic hypertension and 4) chronic hypertension with 
superimposed preeclampsia9. Preeclampsia and eclampsia are among the most common 
forms of hypertensive disease1. Preeclampsia is defined as new onset hypertension (blood 
pressure > 140/90) and proteinuria (> 0.3 g protein in 24 hrs.) after 20 weeks gestation in 
a previously normotensive woman. Eclampsia is defined as grand mal seizures in a 
woman with either gestational hypertension or preeclampsia1. While rates of 
preeclampsia and eclampsia have decreased steadily in developed countries, these 
disorders still contribute to a high proportion of maternal deaths1.  
Globally and within the United States, prominent racial and ethnic disparities 
exist in both hypertensive disease and preterm birth. Non-Hispanic black women are at 
the highest risk for hypertensive disease in pregnancy and associated infant and maternal 
morbidity and mortality10. Even when controlling for access to healthcare, non-Hispanic 
black women have increased rates of hypertensive disease11,12. Additionally, studies have 
shown that black women are three times more likely to die from preeclampsia than white 
women10. Furthermore, in 2014, non-Hispanic black women had a preterm birth rate of 
16.3% and infant mortality of 11.1 per 1000 live births whereas non-Hispanic white 
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women had a preterm birth rate of 10.1% and an infant mortality of 5.1 per 1000 live 
births13,14.  
The etiology of preeclampsia remains poorly understood, however its 
pathophysiology is generally well accepted. In a normal pregnancy, the placenta properly 
responds to an increased fetal demand for oxygen and nutrients from the maternal blood 
supply in the second and third trimesters15. Cytotrophoblasts in the villi of the placenta 
extend into the maternal spiral arteries, the end arteries of the uteroplacental circulation 
that deliver blood directly into the placental intervillous space15. Cytotrophoblasts replace 
the endothelium of the spiral arteries with fibrinoid material, which allows for arterial 
dilation and facilitates the delivery of oxygen and nutrients to the placenta15.   
Preeclampsia is thought to originate from poor placentation, a condition in which 
cytotrophoblasts inadequately invade the spiral arteries and do not allow for proper 
arterial dilation15. This process is depicted in Figure 1. The cause of impaired 
cytotrophoblast invasion is not known but is thought to be a combination of vascular, 
immunological, environmental, and genetic factors16. As the oxygenation demands of the 
placenta are not met the placenta becomes hypoxic and releases reactive oxygen species 
into the maternal circulation. This leads to maternal endothelial dysfunction, systemic 
inflammation and symptoms of ischemia, necrosis, and hemorrhage of vital organs15,3. 
Additionally, the generalized vasoconstriction that is characteristic of preeclampsia 
suggests an imbalance of two prostaglandins: prostacyclin and thromboxane A217. Both 
result from the metabolism of arachidonic acid but each metabolite has opposing effects 
on the body17. Prostacyclin is metabolized from arachidonic acid in the vessel walls and 
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results in vasodilation, whereas thromboxane is metabolized from arachidonic acid in 
platelets and results in vasoconstriction and platelet activation17. Thus, preeclampsia is 
largely a disease of thromboxane overproduction, oxidative stress, vascular injury from 
endothelial dysfunction, and systemic inflammation17,9. 
Figure 1. Poor placentation and preeclampsia (adapted from Redman et al)15 
 
 “Normal placentation (A) and poor placentation (B) at 15 to 16 weeks of pregnancy. The placenta is linked 
to the maternal decidua by anchoring villi. During normal placentation, cytotrophoblasts (blue) cross these 
placental-maternal bridges and invade the maternal decidua and adjacent spiral arteries. They penetrate the 
walls of the arteries and replace part of the maternal endothelium (yellow), stimulating remodeling of the 
arterial wall such that the smooth muscle is lost and the artery dilates. In the decidua, they are confronted 
by many NK cells (red) and some macrophages (purple). During normal pregnancy, these immune cells 
facilitate deep invasion of cytotrophoblasts into the myometrial segments (A) and promote extensive spiral 
artery remodeling. In the preclinical stage of preeclampsia, invasion is restricted (B) with impaired arterial 
remodeling.” 15 
 
Complications of preeclampsia 
Maternal complications of preeclampsia are largely related to the vascular compromise 
affecting the brain, kidneys, lungs, liver, and small blood vessels3. This results in seizures 
and strokes (eclampsia), renal failure, pulmonary edema, hepatic failure, and 
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thrombocytopenia and disseminated intravascular coagulation, respectively3. An 
additional and severe complication of preeclampsia is HELLP syndrome, characterized 
by hemolysis, elevated liver enzymes, and low platelet count. Though only 10% of 
women with preeclampsia develop this syndrome, it is associated with a still birth rate of 
10-15% and neonatal death rate of 20-25%3. Additional maternal complications are listed 
in Table 1.  
Table 1. Maternal Complications of Preeclampsia3 
Medical Manifestations Obstetric complications 
Seizure Uteroplacental insufficiency  
Cerebral hemorrhage Placental abruption 
Renal failure Increased premature deliveries 
Hepatic rupture or failure Increased cesarean section deliveries 
Pulmonary edema   
 
Prematurity and intrauterine growth restriction are among the most common fetal 
complications associated with preeclampsia. Preterm birth (<37 weeks gestation) is the 
leading cause of infant morbidity and mortality in the United States18.  Preterm infants 
are less likely to survive their first year of life than their term counterparts and those that 
do survive are more likely to suffer long term morbidities, especially if born very pre-
term19. Long term morbidities include developmental delay, vision problems, hearing 
problems, and feeding and breathing difficulties20. While preterm births comprised 11.4% 
of births in the US in 2013, they accounted for 66.3% of infant mortality14. In addition to 
the emotional toll placed on parents caring for infants born < 37 weeks gestation, preterm 
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births are also associated with a societal economic burden of  billions of dollars each 
year5. Though the rate of preterm births decreased from 2007 through 2014, preterm 
births have since been on the rise again20. 
In addition to preterm birth, the vasoconstriction of the maternal vasculature 
impairs the delivery of blood and nutrients to the placental, known as uteroplacental 
insufficiency. If uteroplacental insufficiency persists, intrauterine growth restriction 
(IUGR) may occur3. IUGR is defined as a fetus whose birth weight is below the 10th 
percentile or whose abdominal circumference is below the 2.5th percentile, standardized 
to gestational age21. IUGR prevents the baby from growing to its full potential in utero 
and results in low birth weight, which carries a set of negative infant outcomes 
independent of prematurity. A common outcome is impaired neurologic development 
which contributes to attention and performance deficits later in life21. Table 2 lists the 
fetal complications of preeclampsia.  
Table 2. Fetal Complications of Preeclampsia Related to Prematurity3 
Acute Uteroplacental insufficiency 
Placental infarct and/or abruption 
Intrapartum fetal distress 
Still birth (in severe cases) 
Pulmonary edema  
Chronic Uteroplacental insufficiency 
Asymmetric and symmetric SGA features 
IUGR 
Oligohydramnios 
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Treatment and prevention of preeclampsia 
The only definitive treatment for preeclampsia is delivery3. Therefore, induction 
of labor is indicated for term pregnancies and unstable preterm pregnancies, such as fetal 
or maternal decompensation3. For stable preterm pregnancies, patients are often managed 
with frequent fetal testing on an outpatient basis3. These patients are also given 
betamethasone, a steroid that assists with fetal lung maturation should early induction be 
necessary3. Additionally, patients with preeclampsia are treated with prophylactic 
magnesium sulfate during labor and delivery to prevent seizures, which is continued for 
24-48 hours after delivery3.  
With very limited treatment options for preeclampsia, much of the clinical focus 
is on prevention. It was previously thought that antioxidants such as vitamins C and E 
may counteract the oxidative stress present in preeclampsia, however studies failed to 
show a reduced risk of preeclampsia or negative maternal fetal outcomes9. Studies 
evaluating the preventative effect of calcium, vitamin D, and bed rest also failed to prove 
significant risk reduction9.  The most recent data from the United States Preventive 
Service Task Force suggests that low dose aspirin is the most effective preventative 
method for women at risk for preeclampsia9.  
Aspirin is a non-steroidal anti-inflammatory (NSAID) drug that also has 
analgesic, antipyretic, and antiplatelet properties in a dose dependent mechanism. At high 
doses, aspirin induces anti-inflammatory and analgesic effects, while at low dose aspirin 
has antiplatelet effects. Aspirin irreversibly binds to and inhibits cyclooxygenase, the 
enzyme responsible for converting arachidonic acid to prostaglandins and thromboxanes. 
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Inhibiting thromboxane production reduces its vasoconstrictive and pro-thrombotic 
effects that contribute to the pathophysiology of preeclampsia22.  
 Low dose aspirin (81 mg/day) started in the second trimester in pregnant women 
at risk for preeclampsia has been shown to decrease perinatal morbidity and mortality2. 
Henderson et al performed a systemic evidence review for The United States Preventive 
Service Task Force (USPSTF) of randomized control trials (RCT) assessing benefit and 
harm of LDA in pregnant women at risk for preeclampsia. The study found that women 
randomized to LDA compared to those randomized to placebo had a 24% reduction in 
hypertension incidence (RR 0.76, 95% CI:0.62 -0.95), a 14% decrease in risk of preterm 
births (95% CI: 0.76-0.98), and a 20% decrease in rates of IUGR (95% CI: 0.65 -0.99)2. 
Importantly, no perinatal or maternal harms were identified, even at 18 month follow-up 
visits2. Therefore, the United States Preventive Service Task Force recommends that 
women at risk for developing preeclampsia take daily low dose aspirin beginning at 12-
16 weeks gestation (Table 3).  The American College of Gynecologists and Obstetricians 
(ACOG) originally recommended LDA for a smaller scope of women, including those 
with “a history of early-onset preeclampsia and preterm delivery at less than 34 weeks of 
gestation, or in women with more than one prior pregnancy complicated by 
preeclampsia” 23. In 2016, ACOG expanded their recommendations to those women who 
fall into the high risk category per USPSTF clinical risk assessment23. 
  
 
 
  11 
Table 3. USPSTF Clinical Risk Assessment for Initiation of Low Dose Aspirin24 
Risk Level Risk Factors Recommendation 
High History preeclampsia ± adverse outcomes, multifetal 
gestation, chronic hypertension, type 1 or 2 diabetes, 
renal disease, autoimmune disease 
LDA if ≥1 RF 
Moderate Nulliparity, obesity (BMI >30 kg/m2), Family history 
preeclampsia: mother or sister, Sociodemographics: 
African American, low socioeconomic status, age ≥35 
years, History: low birth weight, SGA, previous 
adverse pregnancy outcomes, ≥10 year pregnancy 
interval 
LDA if ≥2 RFs 
Low Previous uncomplicated full-term delivery No LDA 
            LDA= Low dose Aspirin; RF= Risk Factor; BMI= Body Mass Index; SGA= Small for Gestational Age 
 
The findings by Henderson et al are corroborated by the  Aspirin for Evidence-
Based Preeclampsia Prevention (ASPRE) study. This study was a multicenter, double-
blind, placebo-controlled trial in which 1,776 pregnant women at high risk for 
preeclampsia were randomized to either daily low dose aspirin 150 mg or placebo from 
11-14 weeks gestation to 37 weeks gestation. Among those randomized to aspirin 1.6% 
experienced preterm preeclampsia (preeclampsia before 37 weeks gestation), while those 
randomized to placebo had a preterm preeclampsia rate of 4.3% (OR 0.38; 95% CI: 0.02-
0.74)4. Importantly, there was no significant difference in adverse events between LDA 
and placebo groups4. 
 
Interventional low dose aspirin  
Not only is aspirin a well-known, readily available medication, it has also been shown to 
be cost effective for the healthcare system. Werner et al performed a cost-benefit analysis 
of LDA prophylaxis for preeclampsia and estimated that implementing LDA according to 
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the USPSTF recommendations would save $377.4 million in direct medical care costs 
annually when assuming 4 million births per year25. Despite the recommendations by 
USPSTF and ACOG, the robust evidence that LDA significantly reduces negative 
perinatal outcomes, and its cost effectiveness, it is estimated that in the United States 20-
50% of patients are non-compliant with LDA26,27. 
Improving compliance to LDA is one way to increase implementation. However, 
implementation of LDA has three major stakeholders: the physician/provider prescribing 
the medication, the pharmacist filling the prescription, and the patient taking the 
medication. In addition to the patient, the physician/provider and pharmacist have the 
potential to promote or discourage interventional LDA. Each stakeholder’s barriers to 
use, or determinants of practice, must be identified in order to increase implementation of 
LDA and therefore prevent preeclampsia and other negative maternal and perinatal 
outcomes. 
 
Existing research 
LDA adherence rates 
One of the components of LDA implementation is patient adherence, or compliance, to 
daily LDA. Medication nonadherence is a widespread issue in the United States, 
associated with poor patient outcomes, disease progression, and increased healthcare 
costs28. It is estimated that, in the U.S., the cost of hospital admissions due to 
nonadherence is $100 billion per year28 and that 20-80% of patients have poor 
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compliance29. Current literature suggests that the nonadherence rate of LDA for women 
at risk for preeclampsia ranges between 20-50%26,27.  
Abheiden et al performed a study at VU Medical University Center in Amsterdam 
to determine adherences rate to LDA in pregnant women at high risk for hypertensive 
disease. They utilized the Simplified Medication Adherence Questionnaire (SMAQ) and 
found that almost half of women were non-adherent to LDA. They also utilized a Beliefs 
and Behavior Questionnaire (BBQ) to identify adherence and barriers to LDA use. 
Results from the BBQ revealed that 10% of women were non-adherent due to concerns 
for side effects26.  
   Additionally, Navaratnam et al conducted a prospective cohort study to assess 
LDA adherence and “aspirin non-responsiveness” in women at risk for preeclampsia. 
They described “aspirin non-responsiveness” as a condition in which women experienced 
suboptimal antiplatelet effects from aspirin. Adherence was measured by plasma and 
urine aspirin metabolites at prenatal visits. Results showed that 80% of patients had good 
adherence (taking >85% of their medication). Of the 156 women studied, none were 
determined to be “aspirin non-responsive”, which was attributed to the high rate of 
adherence30. This suggests that the efficacy of aspirin is dependent on adherence.  
 Studies have found that adherence with aspirin influences the effectiveness of 
LDA in preventing preelcampsia31. Wright et al performed a secondary analysis of the 
ASPRE trial to study the impact of adherence on the efficacy of LDA. Adherence was 
determined by counting the number of tablets returned by the patient at each visit (or 
reported over the phone) and subtracting from the number of pills prescribed. Good 
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adherence was defined as taking >85% of pills, moderate as 50-84.9%, and poor as 
<50%. Eight percent of patients had good adherence, 15% had moderate, and 5% had 
poor adherence. Wright found that the rate of preeclampsia was 0.9% in participants 
with aspirin adherence ≥90% (OR 0.24; 95% CI:0.09-0.65) and 3.3% in participants with 
aspirin adherence <90% (OR 0.59; 95% CI:0.23-1.53), compared to placebo31. These 
results suggests that those with adherence >90% may have a 75% risk reduction for 
preeclampsia, compared to a 40% risk reduction with <90% compliance, though this 
study was not adequately powered31.  
 
Barriers to medication adherence 
There are several factors that influence patients’ adherence to medication, including the 
patient, provider, medication, and disease. In regards to the patient, poor adherence can 
be due to poor understanding of disease or medication, lack of support system, and lower 
socioeconomic status and level of education28. One could speculate that the pregnant 
population is unique in several regards which warrant further study: medication has the 
potential to affect mother and fetus, the decision making may be shared among mother 
and social support system, and mothers may be more likely to refrain from taking 
medication due to concerns of teratogenic effects.  
 Boehme et al studied barriers to adherence in HIV anti-retroviral therapies (ART) 
in postpartum women living in southeastern United States. The majority of patients were 
African American (83.3%), single (66.7%), and low-income (55.6%). Focus groups and 
individual interviews revealed that common barriers to HIV care were access to 
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transportation, cost of transportation, time conflicts with work and childcare. Common 
facilitators of compliance were family support, appointment reminders, and wanting to 
stay healthy for themselves and their children32. While the treatment of HIV and 
preeclampsia care are much different, the patient population from the Boehme study 
highly reflects that of Boston Medical Center (BMC). At BMC 77% of patients are 
minorities, of which black and Hispanic are the majority, and 72% come from 
underserved populations, such as low-income33,34.  
 Titilayo et al studied the role of patient sociodemographics and adherence to iron 
supplementation in pregnancy for iron deficiency anemia. Results showed that 37% of 
patients were compliant with iron supplementation for 90 days. Patients that were 
younger, lived in urban areas, received secondary education, and had high income were 
more likely to be adherent. Additionally, patients who presented for their initial prenatal 
visit in the first trimester were 5 times more likely to be compliant than those who 
presented in the third trimester, though timing of initial visit was not analyzed 
independently of the above co-variables. Patients who presented for the initial visit in the 
second trimester were 4 times more likely than those who presented in the third 
trimester35. These studies suggest that patient sociodemographics can affect adherence 
and should therefore be considered when tailoring adherence interventions.  
 
Interventions to improve adherence  
Interventions to increase adherence can be directed toward the patient, provider, or 
medication regimen. Patient-directed interventions may include education of the disease, 
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medication regimen, and the benefits, risk, and side effects of medication28. Another 
commonly used intervention is reminders via text messages, emails, mail, or phone call. 
Importantly, educating the patient’s support system can be vital as many expectant 
mothers of multiple cultures and socioeconomic statuses often consider the input and 
advice of their support system in pregnancy-related decisions36,37. The risk factors for 
non-adherence and common interventions to address those risk factors are listed in Table 
4.  
Table 4. Patient-centered Risk Factors for and Strategies to Reduce Nonadherence28 
Risk Factors Interventional Strategies 
Poor mental health 
Forgetfulness 
Poor understanding of disease or 
medication 
Lack of support system  
Education/counseling 
Informational brochures 
Reminders 
Family support 
 
 
A recent meta-analysis published in the Cochrane Library analyzed data from 182 
RCTs measuring medication adherence in patients who received an adherence 
intervention compared to patients who received no intervention. Due to the complexity 
and diversity of patients, interventions, adherence measurements, treatments, and clinical 
outcomes authors were unable to create a simple taxonomy or generalizable list of 
effective strategies. The authors concluded that it was unclear how to best improve 
medication adherence. The following are results from the most recent RCTs with the 
lowest risk of bias for study design, primary clinical outcome, and measuring adherence. 
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These RCTs compare various adherence interventions, such as education, reminders, and 
family support38.  
Gray et al randomized 127 patients with ocular hypertension to an individualized 
care plan based on that patient’s beliefs and needs. The intervention, administered by a 
nurse for one year, included educating the patient and the patient’s social support as well 
as five in-person or over-the-phone check-ins. Gray found that patients were more likely 
to refill their medication 100% of the time than the control group (70% vs 43%) for the 
first 12 months, though the clinical outcome (intraocular pressure) was not significantly 
improved at 12 or 24 months38.  
Conversely, Morgado et al found that education counseling from pharmacists did 
significantly improve clinical outcomes. One hundred and ninety-seven patients were 
randomized to counseling or usual care. Those that received education had significantly 
lower blood pressure (-6.8 mmHg systolic, -2.9 mmHg diastolic) and higher rates of 
medication compliance (74.5% vs 57.6%) compared to patients receiving usual care38. 
These results highlight the importance of the third stakeholder in the implementation 
process: the pharmacist.  
Lester et al also found a significant improvement in adherence to ART with 
educational material and close patient follow-up. After one initial educational session, 
patients were required to respond to a text asking, “How are you?” from clinical staff. 
Staff was prompted to contact the patient if there was no response or if the patient 
indicated a problem. Lester found that the treatment group was more likely to be adherent 
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(RR non-adherence 0.81; 95% CI: 0.69-0.94) and have suppressed viral loads (RR 
virologic failure 0.84; 95% CI 0.75-0.99)38,39.  
Chung et al assessed the efficacy of both educational sessions and electronic 
reminders to increase adherence. Chung randomized 400 newly diagnosed HIV patients 
prescribed anti-retroviral therapy to: 1) an educational session; 2) an alarm reminder 
device; 3) both interventions; or 4) neither. Chung found that the educational sessions had 
improved adherence after one month (difference in intercepts, 3.58%, 95% CI 0.50%-
6.66%), however improvements in long-term adherence rates at 18 months were not 
statistically significant. Patients that received education were 29% less likely to have 
adherence rates < 80% (p=0.055) and 59% less likely to experience viral failure (HIV-1 
RNA >5,000 copies/ml; p=0.01) over 18 months compared to those who did not receive 
education. Alarm reminders had no significant effect on adherence or clinical 
outcomes38,40. Two other RCTs not included in the meta-analysis also found that 
automated reminders did not significantly increase medication adherence41,42.  
The COM99 study, excluded from the Cochrane meta-analysis due to a follow up 
rate <80%, used a combination of education and family support to increase adherence. 
Physicians conducted a 3-part educational session to patients and their families and 
designated a family member to support the patients medication adherence. Patients that 
received the intervention (n=418) were more likely to have a lower blood pressure (OR 
0.62, 95% CI:0.50-0.78) and have a higher rate of compliance (OR 1.91, 95% CI:1.19-
3.05) than control patients at 6 months38,43. In summary, the above RCTs found that 
education often improved adherence rates, with mixed effect on clinical outcome, 
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reminders were ineffective at improving adherence, and increasing family support 
improved adherence and clinical outcomes. 
A recent qualitative comparative analysis (QCA) attempted to synthesize the often 
complex findings of medication adherence meta-analysis. Rather than analyzing data 
based on adherence intervention type, Kahwati et al analyzed systematic reviews based 
on behavior change techniques (BCTs). They described nine different BCTs: knowledge, 
awareness, attitudes, self-efficacy, intention formation, action control, maintenance, 
facilitation, and motivational interviewing (Table 5). The goal of this QCA was to 
identify the BCTs necessary and/or sufficient to increase medication adherence.  
Table 5. Behavior Change Technique Descriptions44 
Behavior Change 
Technique 
Description 
Knowledge (K) General information about behavior-related health 
consequences, use of individualized information, increase in 
understanding/memory enhancement 
Awareness (R)  Risk communication, self-monitoring, reflective listening, 
behavioral feedback 
Attitudes (T) Targets attitudes toward behavior 
Self-efficacy (S) Modeling, practice/skills, training, verbal persuasion, coping 
response, graded tasks, reattribution of success/failure 
Intention formation 
(I) 
General intention, medication schedule, goals, behavioral 
contract 
Action control (C) Cues/reminders, self-persuasion, social support 
Maintenance (M) Maintenance goals, relapse prevention 
Facilitation (F) Ongoing professional support, dealing with adverse effects, 
individualizing/simplifying regimen, reducing environmental 
barriers 
Motivational 
Interviewing (G) 
Client-centered yet directive counseling style that facilitates 
behavior change through helping clients resolve ambivalence 
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Kahwati found that 34 of the 60 trials found improvements in medication 
adherence. Of these 60 trials, none showed a single BCT to be both necessary (BCT 
always present when adherence improved) and sufficient (adherence always improved 
with BCT present). Knowledge was the only necessary individual BCT and improving 
self-efficacy and attitudes were individually sufficient. The combination of increasing 
knowledge and self-efficacy was most common among trials that found improved 
adherence (50% of studies).  Kahwati found six other combinations of BCTs found in a 
smaller number of studies that improved adherence (Table 6). Though these data do not 
include a pregnant population, it provides evidence on the efficacy of various 
interventional strategies and behavior change techniques to increase medication 
adherence44. 
Table 6. BCT combinations used in effective interventions to improve adherence44 
Combination % of studies (#) 
KS 
fG 
rSIT 
kfCm 
fSmIT 
KRFICm 
KrFT 
50 (17) 
12 (4) 
6 (2) 
3 (1) 
6 (2) 
6 (2) 
9 (3) 
Upper case= presence of BCT, Lower case=absence of BCT 
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While there is recent data on medication adherence rates in pregnancy and 
barriers and facilitators of medication adherence in pregnancy, there is little data on 
interventions to increase adherence during pregnancy. Our study aims to fill this 
knowledge gap by implementing several interventions and measuring adherence rates to 
LDA for women at risk for preeclampsia.   
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METHODS 
Study design 
This quality improvement (QI) project at the Boston Medical Center Obstetrics and 
Gynecology (OB/GYN) Department will assess the efficacy of implementation strategies 
to increase patient adherence with low dose aspirin. Though implementation science and 
improvement science are separate fields, this study focuses on QI research addressing the 
implementation of medication adherence interventions.  This study design will take into 
account the diverse patient population at BMC, where 32% of patients are non-English 
speaking, by using the Interpreter Services Department for office appointments and data 
collection. This service is available 24 hours a day, 365 days a year for in-person, video, 
and phone interpreting of 240 different languages. The most commonly interpreted 
languages include Spanish (55%), Haitian/French (14%), Cape Verdean (6%), and 
Portuguese (6%)33. Though a highly effective service, the need for interpretation has the 
potential to prolong intervention administration and data collection, and there is potential 
for language barriers. This protocol was adapted from a study supported by a grant from 
the foundation March Of Dimes, Massachusetts Chapter, for a project entitled, “Low-
Dose Aspirin Intervention”. Dr. Jodi Abbott was a Principal Investigator and has 
consented to the repurposing of the protocol for this thesis. 
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Aim 
The aim of this QI project is to increase patient adherence with LDA for pregnant women 
at risk for preeclampsia within BMC system to 90% in 12 months.  
 
Study population and sampling 
Boston Medical Center (BMC) is the largest safety net hospital in New England, with 
over 70% of patients being a racial/ethnic minority, the majority of which are Hispanic 
and black33. Non-Hispanic black women have been shown to have a higher risk of 
hypertensive disease in pregnancy, a higher risk of complications due to hypertensive 
disease, and a higher rate of preterm births compared to non-Hispanic white 
women13,14,10. The rate of preterm births at BMC is 9.9%, many of which are medically 
indicated due to hypertensive disease45. Therefore, the patient population at BMC has the 
potential to benefit greatly from LDA.  
Programs have been developed at BMC to attempt to reduce the rate of preterm 
births. The OBGYN department at BMC has studied and successfully increased the use 
of progesterone in women at risk for spontaneous preterm, decreasing the rate of 
recurrent preterm birth by 73%46. However, there is currently no published data regarding 
patient adherence rates to LDA and interventions to increase LDA adherence at Boston 
Medical Center.  
 The sample population will include pregnant women at their initial prenatal visit 
between 12-16 weeks gestation at the BMC OBGYN clinic that are at moderate or high 
risk for preeclampsia, as determined by physician screening using the USPSTF criteria, 
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who have been prescribed low dose aspirin (Table 7). We estimate 50 participants a 
month to be eligible for LDA and will obtain data from all participants. Prior studies 
estimate LDA adherence to be between 50-80%26,30, giving an average of 65% 
adherence. Therefore, with an alpha of 0.05, a power of 80%, and an adherence rate of 
65%, 60 subjects are required in the baseline adherence group and 50 patients in the 
post-intervention adherence group to detect an adherence rate of 89%, which is within 
our goal adherence rate of 90%. 
Table 7. Inclusion and Exclusion Criteria  
Inclusion  Exclusion  
12-16 weeks gestation at initial prenatal 
visit 
Prescribed LDA 
 
AND 
One or more: 
- History preeclampsia ± adverse 
outcomes 
- Multifetal gestation 
- Chronic hypertension 
- Type 1 or 2 diabetes 
- Renal disease 
- Autoimmune disease 
 
OR 
Two or more: 
- Nulliparity 
- Obesity (BMI >30 kg/m2) 
- Family history preeclampsia: mother or 
sister 
- Sociodemographics: African American, 
low socioeconomic status, Age ≥35 years 
- History: low birth weight, SGA, 
previous adverse pregnancy outcomes, 
≥10 year pregnancy interval 
 
Contraindication to aspirin  
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Measures 
The primary outcome measure is the percent of patients that are adherent with LDA three 
weeks after receiving a prescription. Adherence will be defined as having a negative 
Simplified Medication Adherence Questionnaire (SMAQ). The SMAQ is a self-report 
questionnaire with 6 items assessing adherence: (1) Do you ever forget to take your 
medication?; (2) Are you careless at times about taking your medication?; (3) Sometimes 
if you feel worse, do you stop taking your medicines?; (4) Thinking about the last week, 
how often have you not taken your medicine?; (5) Did you not take any of your 
medication over the  past weekend?; (6) Over the past 3 months, how many days have 
you not taken any medicine at all?. A positive SMAQ is defined as a positive response to 
any qualitive question, more than two missed doses in the past week, or greater than 2 
days of non-medication over the past 3 months. The SMAQ has a sensitivity of 72%, a 
specificity of 91%, and a Cronbach’s alpha value of 0.75, which is above the acceptable 
threshold of 0.747. 
 There is currently no gold standard to measure medication adherence. Other 
methods include pill counting, biological assays, and microelectronic even monitoring 
systems (MEMS). Pill counting would require close in-person follow-up, which is not 
practical for this study proposal. Measuring biological assays, such as urine and blood 
levels for aspirin metabolites, and MEMS would slow data collection and would be an 
additional cost to the study. Another common measurement of adherence is pharmacy 
refill information, which we will use as our process measure.  
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The process measure is the percent of prescriptions filled within 1 week of the 
initial prenatal appointment (as determined by pharmacy records). Process measures will 
help the improvement team assess if the intervention is successful without having to wait 
for adherence results. The balance measure is the number of minutes providers spend 
with patients. Balance measures will help the improvement team assess if the intervention 
is associated with unwanted side effects in the clinic. Demographics will be measured at 
the end of the SMAQ. Age and income will be asked as open-ended questions, while race 
and education will be asked as multiple-choice questions.  
 
Recruitment 
We expect approximately 50 patients per month to be eligible for aspirin. We will collect 
data on each patient who presents for her initial prenatal visit who meets inclusion 
criteria. Regarding the improvement team, a sign-up sheet will be posted in the OBGYN 
clinic for various physicians, clinicians, nursing, and clerical staff to participate in this 
improvement project. We will discuss with the staff potential interventions that may 
increase patient adherence without causing significant delays in work flow within the 
clinic. Interested staff will receive a short (1 hour) training session that will encompass 
how to properly administer interventions and record data. 
 
Interventions 
Education and recruiting family support have been shown to be effective while there are 
conflicting results regarding the efficacy of reminders for increasing adherence38,32. 
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Therefore, we will aim to use education, family support and phone call reminders as our 
major interventions. Possible educational interventions include physician to patient 
counseling during their appointment, with appropriate interpreter services, educational 
videos played in the clinic waiting room, and education aimed at the patient’s family to 
increase social support.  
However, as previously discussed (Introduction: Statement of Problem), assessing 
for the determinants of practice is crucial in increasing implementation and improving 
health outcomes. Therefore, we will perform an initial barrier analysis in order to 
understand why patients are non-adherent with LDA. A barrier analysis is a rapid 
assessment tool used to understand the determinants of behavior and to produce the most 
effective methods for change based on those determinants. There are seven steps in a 
barrier analysis: 1) define the goal, behavior, and target group; 2) develop the behavior 
question; 3) develop questions about determinants; 4) organize the analysis session; 5) 
collect field data results; 6) organize and analyze the results; and 7) use the results. The 
barrier analysis will guide our interventions. For example, if the barrier analysis reveals 
the major determinants of LDA adherence are lack of belief in aspirin, lack of 
understanding due to language barrier, or lack of family support with adherence, our 
interventions will focus on medication education, increased use of interpreter services, 
and family education of disease and medication, respectively.  
The initial intervention will be administered to patients who are at risk for 
preeclampsia during their initial prenatal visit and have been prescribed LDA. The 
physician/designated clinician will administer the intervention and document that 
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intervention in the electronic medical record. Subsequent interventions will be 
determined by plan-study-do-act (PDSA) cycles.  
PDSA cycles are used to test a change, learn from the results, and create a new 
test. During the “plan” step, a test and data collection plan is determined. The test is 
carried out during the “do” step and results are collected and analyzed during the “study” 
step. Finally, the during “act” step, changes are made to the original test based on the data 
analysis. We will use PDSA cycles to determine how adherence rates change based on 
our intervention choice. We will then use the data analysis to choose interventions that 
would likely increase adherence.  
In addition to adherence, pharmacy information and length of appointment data 
will be used to guide intervention choices. If, for example, we find many patients are not 
filling their prescriptions or appointments are running twice as long as before the 
intervention, we can change our interventions appropriately.  
 
Data collection 
Simple random sampling will be used to collect baseline adherence data. The 
improvement team will randomly select 60 electronic medical records of patients who 
were prescribed LDA at their first prenatal visit within the last 3 weeks. We will contact 
those 60 women via phone and administer the Simplified Medication Adherence 
Questionnaire (SMAQ). This same survey will be used to assess adherence, our outcome 
measure, among 50 people three weeks after the intervention is implemented. This allows 
one week for patients to fill their prescriptions before assessing adherence over two 
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weeks. Staff will collect demographic information directly after administering the 
SMAQ. 
 Staff will collect prescription filling data, our process measure, by calling the 
patient’s pharmacy 1 week after their appointment to determine if the patient has picked 
up and filled the prescription. Staff will collect appointment times, our balance measure, 
by using the “room in” and “check out” times recorded in the electronic medical records. 
The times are entered into the EMR by clerical and nursing staff as the patient navigates 
throughout the clinic. Demographics, adherence, pharmacy information, and length of 
appointment for each patient will then be transferred to an excel sheet. Data will be 
collected weekly for 12 months.  
 
Data analysis 
Adherence data will be analyzed with run charts, where percent adherence (# patients 
with a negative SMAQ divided by # of patients with an SMAQ score obtained) is the y-
axis and time is the x-axis. If the change in adherence is not obvious, a chi square test 
will be used to determine if there is a difference in adherence over two weeks between 
two groups that received different interventions. Data may be stratified by age, race, 
socioeconomic status, and level of education to assess for impact on adherence.  
The association between intervention type, a categorical independent variable, 
and pharmacy information, a categorical dependent variable (filled/not filled), will be 
explored using a chi square test. The association between intervention type, a categorical 
independent variable, and length of appointment, a continuous dependent variable, will 
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be explored using a one way ANOVA followed by simple linear regression test to adjust 
for cofounders. 
 
Timeline and resources 
The timeline for this study proposal requires 3 months for preparation and 12 months for 
data collection, as outlined in Table 8. Resources required include working space for 1-2 
research assistants in the OBGYN clinic, in addition to the clinical personnel of the 
improvement team. The duties of the clinical personnel include administering the 
intervention, recording the intervention in the electronic medical record, and 
documenting “room in” and “check out” times. The responsibilities of the research 
assistants include administering the SMAQ and records results, collecting pharmacy refill 
information, measuring length of appointments, transferring data to excel sheets, and 
analyzing data.  
Table 8. Study Proposal Timeline  
Date Tasks 
May 2018 Submit to IRB 
Assemble improvement team and assign roles 
June 2018 Meeting/training with clinical staff 
Perform barrier analysis  
July 2018 Perform initial chart review for baseline adherence  
Roll out phase 
August 2018 to August 2019 Data analysis, PDSA cycle (monthly x 12) 
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Institutional Review Board 
This study proposal will be submitted to the Institutional Review Board of the Boston 
University Medical Center for full review. Full review is necessary as the subjects are 
pregnant women. However, no special research precautions are necessary as this project 
is not a direct study of risks and benefits of aspirin, subjects will not be receiving MRIs, 
and aspirin has not been shown to place subjects/fetus at greater than minimal risk.  
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CONCLUSION 
Discussion 
Several limitations exist within this study proposal. One major limitation is measuring 
adherence by self-report. Self-report is limited by the patient’s ability to understand items 
and willingness to disclose information41. Some studies have shown that other methods of 
measurement, such as pill counts, microelectronic event monitoring systems, and 
biological assays, are less likely to over-estimate adherence41. However, self-report is an 
inexpensive, practical option for this QI study. The goal of quality improvement is to 
collect just enough data to inform improvement. Therefore, though the absolute 
adherence rate may be overestimated, the relative change in adherence rates will be 
extremely useful in this setting. Additionally, we will be collecting pharmacy refill 
information, which has been shown to bolster self-report data49.  
Secondly, this study is designed to only measure adherence over two weeks. 
Therefore, important information regarding adherence rates, facilitators, barriers and 
effective interventions for long-term adherence will not be addressed. Assessing long-
term adherence is important as patients are expected to be adherent to LDA for several 
months in order to maximize the reduction in risk for preeclampsia.  
Finally, this study is limited in its generalizability of study findings. As discussed 
by Grimshaw et al, implementation strategies often need to be adapted to specific patient 
populations and healthcare settings24. Therefore, strategies that increase adherence to 
LDA in pregnant women at BMC may not be as effective at different institutions or 
among different patient populations.  
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Though these limitations exist, this study does utilize barrier analysis, which 
many studies often lack24.  Therefore, this design has the potential to identify the most 
effective strategies to increase medication adherence, which can then be tailored to 
various patient populations, diseases, and medications to improve healthcare outcomes 
and reduce healthcare costs.  Future studies should explore interventions for other key 
stakeholders, namely providers and pharmacists, to increase LDA adherence.  
  
Summary 
Low dose aspirin is recommended for women at risk for preeclampsia. Preeclampsia is 
defined as new onset hypertension (blood pressure > 140/90) and proteinuria (> 0.3 g 
protein in 24 hrs.) after 20 weeks gestation in a previously normotensive woman. Risk 
factors for developing preeclampsia include chronic hypertension, diabetes, obesity, 
African American race, low social economic status, personal or family history of 
preeclampsia, among others1. Despite this inexpensive, easy to administer, safe, 
potentially life-saving intervention, many women who at risk for preeclampsia are 
nonadherent to LDA. 
 Research on medication adherence has shown that nonadherence can be due to 
poor understanding of disease or medication, lack of support system, and lower 
socioeconomic status and level of education30. The literature suggests that providing 
education and family support to patients increases medication adherence38. However, 
these studies often have conflicting results. Some studies have found reminders to be 
effective while others have not32,40, and other studies have found education to be effective 
depending on who provides the education39,43,50. The literature also notes that there are 
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specific barriers to medication adherence in the pregnant population. While there is data 
on interventions to increase medication nonadherence for patients with diseases such as 
chronic hypertension and HIV in a non-pregnant population, there is a gap in existing 
literature describing interventions to increase medication adherence during pregnancy. 
This study design addresses these gaps in knowledge, in both barriers to medication 
adherence and effective patient-directed implementation strategies. 
  
Clinical and/or public health significance 
Hypertensive disease, including preeclampsia, is the leading cause of perinatal morbidity 
and mortality and is associated with approximately 3.8% of pregnancies in the United 
States2. Globally, preeclampsia accounts for approximately 50,000 maternal deaths every 
year10. Additionally, hypertensive disease in pregnancy contributes to 15% of preterm 
births1. Prematurity is the leading cause of infant morbidity and mortality in the United 
States18, with negative fetal outcomes such as developmental delay, hearing and 
breathing impairments, and death16. 
 Low dose aspirin has been shown to decrease the rate of preeclampsia1,19 and 
adherence to LDA is integral to the efficacy of the intervention29. However, a high 
proportion of patients, 20-50%, are non-compliant with LDA31. Determining strategies 
that increase adherence to LDA in pregnant women at risk for preeclampsia has the 
potential to reduce negative maternal fetal outcomes for tens of thousands of patients in 
the United States and globally.  
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APPENDIX 
Classification of Professional Interventions from EPOC Taxonomy51: 
 
Audit and feedback A summary of health workers’ performance over a specified period of time, 
given to them in a written, electronic or verbal format. The summary may 
include recommendations for clinical action. 
Clinical incident 
reporting 
System for reporting critical incidents, Monitoring the performance of the 
delivery of healthcare Monitoring of health services by individuals or healthcare 
organizations, for example by comparing with an external standard. 
Communities of 
practice 
Groups of people with a common interest who deepen their knowledge and 
expertise in this area by interacting on an ongoing basis 
Continuous quality 
improvement 
An iterative process to review and improve care that includes involvement of 
healthcare teams, analysis of a process or system, a structured process 
improvement method or problem-solving approach, and use of data analysis to 
assess changes 
Educational games The use of games as an educational strategy to improve standards of care. 
Educational materials Distribution to individuals, or groups, of educational materials to support 
clinical care, i.e., any intervention in which knowledge is distributed. For 
example, this may be facilitated by the internet, learning critical appraisal skills; 
skills for electronic retrieval of information, diagnostic formulation; question 
formulation 
Educational meetings Courses, workshops, conferences or other educational meetings 
Educational outreach 
visits, or academic 
detailing 
Personal visits by a trained person to health workers in their own settings, to 
provide information with the aim of changing practice. 
Clinical Practice 
Guidelines 
Clinical guidelines are systematically developed statements to assist healthcare 
providers and patients to decide on appropriate health care for specific clinical 
circumstances'(US IOM) 
Inter-professional 
education 
Continuing education for health professionals that involves more than one 
profession in joint, interactive learning 
Local consensus 
processes 
Formal or informal local consensus processes, for example agreeing a clinical 
protocol to manage a patient group, adapting a guideline for a local health 
system or promoting the implementation of guidelines. 
Local opinion leaders The identification and use of identifiable local opinion leaders to promote good 
clinical practice. 
Managerial 
supervision 
Routine supervision visits by health staff. 
Patient-mediated 
interventions 
Any intervention aimed at changing the performance of healthcare professionals 
through interactions with patients, or information provided by or to patients. 
Public release of 
performance data 
Informing the public about healthcare providers by the release of performance 
data in written or electronic form. 
Reminders Manual or computerized interventions that prompt health workers to perform an 
action during a consultation with a patient, for example computer decision 
support systems. 
Routine patient-
reported outcome 
measures 
Routine administration and reporting of patient reported outcome measures to 
providers and/or patients 
Tailored 
interventions 
Interventions to change practice that are selected based on an assessment of 
barriers to change, for example through interviews or surveys. 
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LIST OF JOURNAL ABBREVIATIONS 
Am Fam Physician American Family Physician Journal 
Ann Behav Med Annals of Behavioral Medicine 
Ann Pharmacother Annals of Pharmacotherapy 
Implement Sci Implementation Science 
Innov Pharm Innovations in Pharmacy 
Int J Clinical Pharm International Journal of Clinical Pharmacy 
J Gen Intneral Med Journal of General Internal Medicine 
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NEJM New England Journal of Medicine 
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